/ /

LATEST

OCTA system offers exquisite views
OCTA system offers exquisite viewsA new high-density OCT angiography system (AngioVueHD, OptoVue) provides exquisite views of the retinal microvasculature without the need for injection of fluorescein dye.
‘What is it with these people?’After being in the field for 35 years, I still wonder, “What is it with these people?” Here are a few other examples of what I learned from those instances.
Engaging OCTA in glaucoma imaging
Engaging OCTA in glaucoma imagingA prospective, observational study found that eyes with mild POAG could be differentiated from pre-perimetric glaucomatous eyes, which also could be differentiated from normal eyes using OCTA-derived retinal vessel density measurements.
Finding a fix for irregular astigmatism after PK Transepithelial topography-guided PRK can help correct irregular astigmatism after penetrating keratoplasty.
Evidence-based ophthalmologyWhy it is that ophthalmologists who read the same papers in the same journals have such widely varying approaches?
Study explores influence of ocular blood flow in course of glaucomaOcular blood flow has been associated with the incidence, prevalence and progression of glaucoma, but its potential causative role remains a subject for debate. Better insights may be on the horizon using OCT angiography and sophisticated mathematical modeling techniques.
Adding electroretinography: Technology to clinical utilityPattern electroretinography (PERG) and visually evoked potential (VEP) tests can objectively evaluate the function of axion and retinal ganglion cells. These test results can add another component in successfully treating patients with cataract and/or glaucoma.
Aqueous angiography: Moving toward individualized IOP control
Aqueous angiography: Moving toward individualized IOP controlAqueous angiography facilitates increased understanding of aqueous humor outflow that can provide individualized treatment for IOP control.
Insights on preventing TRD in PDR patients after Avastin, vitrectomyStudy results provide new information about the risk and strategies for preventing tractional retinal detachment (TRD) development or progression in eyes with severe proliferative diabetic retinopathy (PDR) receiving intravitreal bevacizumab (Avastin, Genentech) prior to vitrectomy.
Novel therapies could stem burden of diabetic eye diseaseA better understanding of the pathophysiologic mechanisms of diabetes has resulted in improved control of its local and systemic comorbidities. Further developments are needed, however, considering the growing number of diabetic patients and who are at risk for late-stage diabetic eye disease.

Poll

View Results